An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor

BACKGROUND: Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP‐ribose) polymerase (PARP) inhibitor olaparib. We performed a single institu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Borazanci, Erkut, Korn, Ronald, Liang, Winnie S., Guarnieri, Carol, Haag, Susan, Snyder, Courtney, Hendrickson, Kristin, Caldwell, Lana, Von Hoff, Dan, Jameson, Gayle
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Gastrointestinal Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964119/
https://ncbi.nlm.nih.gov/pubmed/31391296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0905
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki